The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
University of Utah
ClinicalTrials.gov Identifier:
NCT00811980
First received: December 17, 2008
Last updated: November 23, 2011
Last verified: November 2011

December 17, 2008
November 23, 2011
January 2009
June 2010   (final data collection date for primary outcome measure)
IL-6 [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
Measurement of IL-6 release in response to MRSA.
Not Provided
Complete list of historical versions of study NCT00811980 on ClinicalTrials.gov Archive Site
MCP-1 [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
Measurement of MCP-1 release in response to MRSA.
Not Provided
Not Provided
Not Provided
 
The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

We will determine if linezolid inhibits cellular activation and production of pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and the justification for further investigations in S. Aureus sepsis.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Whole blood

Non-Probability Sample

Healthy subjects who consent to donate blood.

Sepsis
Drug: Linezolid or Vancomycin
Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
Other Name: Zyvox
Heathy Subjects
Intervention: Drug: Linezolid or Vancomycin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
June 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy, taking no medications, and not recently hospitalized

Exclusion Criteria:

  • Infection (active)
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00811980
00392, Pfizer GA5951WK
No
University of Utah
University of Utah
Pfizer
Principal Investigator: Guy Zimmerman, MD University of Utah
University of Utah
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP